Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs | PTCE Pharmacy Connect
Description
Educational Objectives
- Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life
- List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD
Faculty:
Amanda Hickman, PharmD, MPH, MSCS
Central Support Pharmacist – Neuro/Psych/Sleep
Trellis Rx
Atlanta, Georgia
Moderator:
Jessica L. Kerr, PharmD, CDCES
Associate Dean – Office Professional and Student Affairs
Professor/Clinical Pharmacist
Southern Illinois University Edwardsville
School of Pharmacy
Edwardsville, Illinois
Amanda Hickman, PharmD, MPH, MSCS, and Jessica L. Kerr, PharmD, CDCES, have no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.
This activity is supported by an educational grant from Sarepta Therapeutics.
United States
